Andersen TO - Search Results

1

Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state.

Dahm A, Rosendaal FR, Andersen TO, Sandset PM. Dahm A, et al. Among authors: andersen to. Br J Haematol. 2006 Feb;132(3):333-8. doi: 10.1111/j.1365-2141.2005.05876.x. Br J Haematol. 2006. PMID: 16409298 Free article.

2

Impaired circadian variations of haemostatic and fibrinolytic parameters in tetraplegia.

Iversen PO, Groot PD, Hjeltnes N, Andersen TO, Mowinckel MC, Sandset PM. Iversen PO, et al. Among authors: andersen to. Br J Haematol. 2002 Dec;119(4):1011-6. doi: 10.1046/j.1365-2141.2002.03953.x. Br J Haematol. 2002. PMID: 12472582 Free article.

3

Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.

Bendz B, Hansen JB, Andersen TO, Ostergaard P, Sandset PM. Bendz B, et al. Among authors: andersen to. Br J Haematol. 1999 Dec;107(4):756-62. doi: 10.1046/j.1365-2141.1999.01791.x. Br J Haematol. 1999. PMID: 10606880 Free article. Clinical Trial.

4

A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1.

Bendz B, Andersen TO, Sandset PM. Bendz B, et al. Among authors: andersen to. Thromb Res. 2000 Mar 15;97(6):463-72. doi: 10.1016/s0049-3848(99)00183-8. Thromb Res. 2000. PMID: 10704656

5

Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins.

Bendz B, Andersen TO, Sandset PM. Bendz B, et al. Among authors: andersen to. Blood Coagul Fibrinolysis. 2000 Jun;11(4):343-8. doi: 10.1097/00001721-200006000-00005. Blood Coagul Fibrinolysis. 2000. PMID: 10847421

6

A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI).

Dahm AE, Andersen TO, Rosendaal F, Sandset PM. Dahm AE, et al. Among authors: andersen to. J Thromb Haemost. 2005 Apr;3(4):651-8. doi: 10.1111/j.1538-7836.2005.01237.x. J Thromb Haemost. 2005. PMID: 15842349 Free article.

7

The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.

Eilertsen AL, Høibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. Eilertsen AL, et al. Among authors: andersen to. Maturitas. 2005 Oct 16;52(2):111-8. doi: 10.1016/j.maturitas.2005.01.004. Maturitas. 2005. PMID: 16186073 Clinical Trial.

8

The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.

Høibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM. Høibraaten E, et al. Among authors: andersen to. Thromb Haemost. 2001 May;85(5):775-81. Thromb Haemost. 2001. PMID: 11372667 Clinical Trial.

9

Low molecular weight heparin prevents activation of coagulation in a hypobaric environment.

Bendz B, Sevre K, Andersen TO, Sandset PM. Bendz B, et al. Among authors: andersen to. Blood Coagul Fibrinolysis. 2001 Jul;12(5):371-4. doi: 10.1097/00001721-200107000-00006. Blood Coagul Fibrinolysis. 2001. PMID: 11505080 Clinical Trial.

10

Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.

Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Eilertsen AL, et al. Among authors: andersen to. Thromb Res. 2007;120(3):371-9. doi: 10.1016/j.thromres.2006.10.013. Epub 2006 Dec 15. Thromb Res. 2007. PMID: 17156824 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters